Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) for Preventing Recurrent Clostridioides difficile Infection in the US.
Saved in:
| Title: | Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) for Preventing Recurrent Clostridioides difficile Infection in the US. |
|---|---|
| Authors: | Lodise T; Albany College of Pharmacy and Health Sciences, Albany, NY, USA., Guo A; Medical Affairs, Ferring Pharmaceuticals, Inc, 100 Interpace Parkway, Parsippany, NJ, 07054, USA. amy.guo@ferring.com., Yang M; Analysis Group, Boston, MA, USA., Cook EE; Analysis Group, Boston, MA, USA., Song W; Analysis Group, Boston, MA, USA., Yang D; Analysis Group, Boston, MA, USA., Wang Q; Analysis Group, London, UK., Zhao A; Analysis Group, Boston, MA, USA., Bochan M; Outpatient Integrated Strategies, Carmel, IN, USA. |
| Source: | Advances in therapy [Adv Ther] 2023 Jun; Vol. 40 (6), pp. 2801-2819. Date of Electronic Publication: 2023 Apr 24. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Health Communications Inc Country of Publication: United States NLM ID: 8611864 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1865-8652 (Electronic) Linking ISSN: 0741238X NLM ISO Abbreviation: Adv Ther |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
